{"references": ["Vol 93, N\u00ba 2, P\u00e1gs 240-246. 2018. Nehra AK, Alexander JA, Loftus CG, et al. Proton pump inhibitors: review of emerging concerns. Mayo Clin Proc. Doi: http://dx.doi.org/10.1016/j.mayocp.2017.10.022", "Vol 68, N\u00ba 2, P\u00e1gs 374-376. 2019. Peng Y-C, Huang L-R, Lin C-L, et al. Association between proton pump inhibitors use and risk of gastric cancer in patients with GERD. Gut. Doi: http://dx.doi.org/10.1136/gutjnl-2018-316057", "Vol 67, N\u00ba 10, P\u00e1gs 1908-1910. 2018. Niikura R, Hayakawa Y, Hirata Y, et al. Long-term proton pump inhibitor use is a risk factor of gastric cancer after treatment for Helicobacter pylori: a retrospective cohort analysis. Gut. Doi: http://dx.doi.org/10.1136/gutjnl-2017-315710", "Vol 7, N\u00ba 10, P\u00e1gs. 2017. Brusselaers N, Wahlin K, Engstrand L, et al. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden. BMJ Open. Doi: http://dx.doi.org/10.1136/bmjopen-2017-017739", "Vol 100, P\u00e1gs 1503-1507. 2019. Poulsen AH, Christensen S, McLaughlin JK, et al. Proton pump inhibitors and risk of gastric cancer: a population-based cohort study. Br J Cancer. Doi: http://dx.doi.org/10.1038/sj.bjc.6605024", "Vol. 31, P\u00e1gs 675-684. 2008. Tamim H, Duranceau A, Chen L-Q, et al. Association between use of acidsuppressive drugs and risk of gastric cancer. A nested case-control study. Drug Saf. Doi: http://dx.doi.org/10.2165/00002018-200831080-00004", "Vol 55, N\u00ba 11, P\u00e1gs 1538-1544. 2006. Garc\u00eda Rodr\u00edguez LA, Lagergren J, Lindblad M. Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK. Gut. Doi: http://dx.doi.org/10.1136/gut.2005.086579", "Vol 123, P\u00e1gs 307-315. 2020. Liu P, McMenamin \u00dana C, Johnston BT, et al. Use of proton pump inhibitors and histamine-2 receptor antagonists and risk of gastric cancer in two population-based studies. Br J Cancer. Doi: http://dx.doi.org/10.1038/s41416-020-0860-4", "Vol 115, N\u00ba 5, P\u00e1gs 705-715. 2020. Lee JK, Merchant SA, Schneider JL, et al. Proton pump inhibitor use and risk of gastric, colorectal, liver, and pancreatic cancers in a community-based population. Am J Gastroenterol. Doi: http://dx.doi.org/10.14309/ajg.0000000000000591", "Vol 70, N\u00ba 11, P\u00e1gs 2066-2075. 2021. Seo SI, Park CH, You SC, et al. Association between proton pump inhibitor use and gastric cancer: a population-based cohort study using two different types of nationwide databases in Korea. Gut. Doi: http://dx.doi.org/10.1136/gutjnl-2020-323845", "Vol 116, N\u00ba 6, P\u00e1gs 1211-1219. 2021. Shin G-Y, Park JM, Hong J, et al. Use of proton pump inhibitors vs histamine 2 receptor antagonists for the risk of gastric cancer: population-based cohort study. Am J Gastroenterol. Doi: http://dx.doi.org/10.14309/ajg.0000000000001167", "Vol 2, N\u00ba 4, P\u00e1gs 165-170. 2020. Kuiper JG, Herk-Sukel MPP, Lemmens VEPP, et al. Proton pump inhibitors are not associated with an increased risk of colorectal cancer. GastroHep. Doi: https://doi.org/10.1002/ygh2.409", "Vol 12. 2017. Hwang IC, Chang J, Park SM. Emerging hazard effects of proton pump inhibitor on the risk of colorectal cancer in low-risk populations: a Korean nationwide prospective cohort study. PLoS One. Doi: https://doi.org/10.1371/journal.pone.0189114", "Vol 9, N\u00ba 2, P\u00e1gs 192-193. 2013. Lai S-W, Liao K-F, Lai H-C, et al. Use of proton pump inhibitors correlates with increased risk of colorectal cancer in Taiwan. Asia Pac J Clin Oncol", "Vol 18, N\u00ba 7, P\u00e1gs 540-544. 2009. Chubak J, Boudreau DM, Rulyak SJ, et al. Colorectal cancer risk in relation to use of acid suppressive medications. Pharmacoepidemiol Drug Saf. Doi: https://doi.org/10.1002/pds.1749", "Vol 103, N\u00ba 4, P\u00e1gs 966-973. 2008. Van Soest EM, van Rossum LGM, Dieleman JP, et al. Proton pump inhibitors and the risk of colorectal cancer. Am J Gastroenterol. Doi: http://dx.doi.org/10.1111/j.1572-0241.2007.01665.x", "Vol 133, N\u00ba 3, P\u00e1gs 755-760. 2007. Robertson DJ, Larsson H, Friis S, et al. Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study. Gastroenterology. Doi; https://doi.org/10.1053/j.gastro.2007.06.014", "Vol 133, N\u00ba 3, P\u00e1gs 748-754. 2007. Yang Y-X, Hennessy S, Propert K, et al. Chronic proton pump inhibitor therapy and the risk of colorectal cancer. Gastroenterology. Doi: http://dx.doi.org/10.1053/j.gastro.2007.06.022", "Vol 115, N\u00ba 5, P\u00e1gs 706-715. 2020. Lee JK, Merchant SA, Schneider JL, et al. Proton pump inhibitor use and risk of gastric, colorectal, liver, and pancreatic cancers in a community-based population. Am J Gastroenterol. Doi: http://dx.doi.org/10.14309/ajg.0000000000000591", "Vol 123, P\u00e1gs 844-851. 2020. Babic A, Zhang X, Morales-Oyarvide V, et al. Acid-suppressive medications and risk of colorectal cancer: results from three large prospective cohort studies. Br J Cancer. Doi: http://dx.doi.org/10.1038/s41416-020-0939-y", "Vol 45, N\u00ba 1, P\u00e1g 101397. 2021. Lei W-Y, Wang J-H, Yi C-H, et al. Association between use of proton pump inhibitors and colorectal cancer: a nationwide population-based study. Clin Res Hepatol Gastroenterol. Doi: https://doi.org/10.1016/j.clinre.2020.02.017"]}

En un contexto de uso muy extendido y prolongado en la población de fármacos inhibidores de la bomba de protones, surge la necesidad de determinar los riesgos de su uso a largo plazo. Se presentan dos artículos, surgidos de la misma cohorte poblacional británica, que comparan el riesgo de cáncer gástrico y colorrectal entre pacientes usuarios de fármacos inhibidores de la bomba de protones y de fármacos antagonistas de los receptores H2 de la histamina. In a context of widespread and prolonged use of proton pump inhibitor drugs in the population, there is a need to determine the risks of their long-term use. These are two articles from the same British population-based cohort, that compare the risk of gastric and colorectal cancer among patients who use proton pump inhibitor drugs and histamine H2 receptor antagonist drugs